Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic
N
N
Sersa
I
I
Jevtic
V
V
Tomsic
M
M
Praprotnik
S
S
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D000069285:Infliximab; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab